Actelion's Founding Couple Starts New Biotech, With J & J's Backing

The founders of Swiss biotech company Actelion, which has been sold to J&J, are starting over again —creating a new biotech player with nearly $1 billion in capital, a deep-pocketed partner in J&J and soon, a stock listing in Zurich.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news